Melissa Jane FULLWOOD

Despite remarkable progress towards personalized human genome sequencing, much about the human genome remains unknown. Only 2% of the human genome codes for protein, yet many studies suggest that the remaining 98% may have non-coding functions and may be related to disease. Recently, tremendous advances in DNA sequencing throughput, speed, and cost have been made by next-generation sequencing, allowing the development of new genomic technologies for powerful ultra-high-throughput, genome-wide annotation of genomic elements.


Principal Investigator, Cancer Science Institute of Singapore, National University of Singapore
Nanyang Assistant Professor, School of Biological Sciences, Nanyang Technological University
Adjunct Principal Investigator, Institute of Molecular and Cell Biology, A*STAR Singapore

Year(s) Degree (if applicable) Institute
2009 Ph.D. National University of Singapore, Singapore
2005 B.Sc.(Hons) Stanford University, USA
2010 – 2012 Lee Kuan Yew Post-Doctoral Fellow, A*STAR-Duke-NUS NRP
2011 – 2012 Adjunct Research Fellow, Department of Biochemistry, National University of Singapore
2011 – 2012 Adjunct Post-Doctoral Fellow, Genome Institute of Singapore
2009 – 2010 Post-Doctoral Fellow, Duke-NUS
2009 Research Fellow, Genome Institute of Singapore
2005 – 2006 Research Officer, Genome Institute of Singapore
2014 A*STAR/SNAS Young Scientist Award
2013 National Research Foundation (NRF) Fellowship
2011 A*STAR Phillip Yeo Prize for Outstanding Achievement in Research (Biomedical)
2010 Regional Winner (International), GE & Science Prize for Young Life Scientists
2010 Lee Kuan Yew Post-Doctoral Fellowship
2009 L’Oreal-UNESCO for Women in Science Singapore National Fellowship
2006 A*STAR National Science Scholarship (A*STAR NSS PhD)
2005 Phi Beta Kappa
2002 A*STAR National Science Scholarship (A*STAR NSS BS)


The Fullwood lab focuses on human genome annotation, transcriptome characterization, and understanding transcription regulation, to promote human personal genomics, particularly in cancer. In vivo, DNA is compacted into chromatin. The processes surrounding DNA are complex, and these “epigenetic” processes can include histone modifications, transcription factors that regulate gene expression. Cancer genome sequencing has revealed that many factors associated with epigenetic processes are mutated in cancers, and epigenetic processes have been targeted by specific drugs. In addition, RNA has been found to be more complex than previously thought, and long non-coding RNAs, previously thought of as “transcriptional noise”, have been found to play roles in cancer.

Chromatin immunoprecipitation (ChIP) with sequencing and RNA sequencing are powerful tools that rely on new next-generation sequencing approaches to provide deep insights into epigenetic processes. Moreover, Dr Fullwood’s research on developing Chromatin Interaction Analysis with Paired-End Tag sequencing (ChIA-PET) has suggested that chromatin interactions, which are regions of the genome that are far apart in the linear genome sequence but come together in close 3-dimensional spatial proximity, may constitute common mechanisms for gene regulation.

Dr Fullwood’s current work focuses on using ChIP sequencing, RNA sequencing, and ChIA-PET on a gastric cancer cell model, as well as other cancer cell models, to elucidate the detailed epigenomic profiles, allowing for new insights into possible cancer-associated biomarkers and cancer therapies. In addition, Dr Fullwood is interested in continuing to develop and refine new genomic technologies to understand chromatin and transcription.

Lab Members